CYTK Q1 2020 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-54.8% YoY

Gross Profit

-$18M-468.3% margin

Operating Income

-$30M-793.8% margin

Net Income

-$39M-1030.2% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

-26.6%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$31M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$257M

Total Liabilities

$302M

Stockholders' Equity

-$46M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$8M	-54.8%
Gross Profit	-$18M	-$15M	-18.8%
Operating Income	-$30M	-$25M	-23.8%
Net Income	-$39M	-$29M	-34.2%

Revenue Segments

Research And Development

$4M62%

Research And Development Milestone Grant And Other Revenues Net

$2M38%